- Home
- RYM vs XFOR Comparison
RYM vs XFOR Comparison
Compare RYM & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYM
- XFOR
- Stock Information
- Founded
- RYM 2016
- XFOR 2014
- Country
- RYM United States
- XFOR United States
- Employees
- RYM N/A
- XFOR N/A
- Industry
- RYM Farming/Seeds/Milling
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RYM Consumer Staples
- XFOR Health Care
- Exchange
- RYM Nasdaq
- XFOR Nasdaq
- Market Cap
- RYM 85.7M
- XFOR 84.3M
- IPO Year
- RYM 2021
- XFOR N/A
- Fundamental
- Price
- RYM $42.91
- XFOR $3.48
- Analyst Decision
- RYM
- XFOR Strong Buy
- Analyst Count
- RYM 0
- XFOR 3
- Target Price
- RYM N/A
- XFOR $34.17
- AVG Volume (30 Days)
- RYM 14.4K
- XFOR 427.9K
- Earning Date
- RYM 11-13-2025
- XFOR 11-12-2025
- Dividend Yield
- RYM N/A
- XFOR N/A
- EPS Growth
- RYM N/A
- XFOR N/A
- EPS
- RYM N/A
- XFOR N/A
- Revenue
- RYM $12,260,000.00
- XFOR $32,774,000.00
- Revenue This Year
- RYM N/A
- XFOR $1,307.51
- Revenue Next Year
- RYM N/A
- XFOR N/A
- P/E Ratio
- RYM N/A
- XFOR N/A
- Revenue Growth
- RYM 186.99
- XFOR 5721.31
- 52 Week Low
- RYM $2.71
- XFOR $1.35
- 52 Week High
- RYM $84.44
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- RYM N/A
- XFOR 54.13
- Support Level
- RYM N/A
- XFOR $3.35
- Resistance Level
- RYM N/A
- XFOR $3.70
- Average True Range (ATR)
- RYM 0.00
- XFOR 0.32
- MACD
- RYM 0.00
- XFOR -0.01
- Stochastic Oscillator
- RYM 0.00
- XFOR 71.43
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.